Please provide your email address to receive an email when new articles are posted on . Pegcetacoplan led to greater improvements in hemoglobin compared with eculizumab among patients with paroxysmal ...

The paroxysmal nocturnal hemoglobinuria market is witnessing robust growth, driven by increasing disease awareness, improved diagnostics, and the expanding adoption of targeted therapies. The approval ...

Please provide your email address to receive an email when new articles are posted on . Crovalimab provided disease control and proved noninferior to a current standard-of-care treatment for certain ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, progressive, multi-system, life-threatening disease, and diagnosing it early in the clinical course is essential for optimizing management ...

These findings suggest that clone size at PNH onset may serve as a prognostic factor for disease burden and MAVEs/TEs, aiding in clinical decision-making about treatment initiation or maintenance. In ...

Post hoc analyses of the phase 3 PEGASUS trial found that clinical and hematological improvements were associated with better patient-reported fatigue and physical function outcomes in paroxysmal ...

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Paroxysmal Nocturnal Hemoglobinuria pipeline constitutes 20+ key companies continuously working towards developing 25+ ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disease in which the immune system breaks apart the red blood cells (RBCs) in the body. The medical term for this premature rupture of RBCs is ...

We have recently had the opportunity of studying a case of march hemoglobinuria in a young woman in whom attacks were precipitated by short walks. The present communication describes the clinical and ...

BOSTON, April 5, 2011 (GLOBE NEWSWIRE) -- Oncology Care Live (www.OncologyCarelive.com ), the live online oncology congress, today announced that Michael J. Borowitz ...

Basel, December 6, 2024 – Novartis today announced positive topline results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta ® ...